Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2010
09/15/2010CN101137363B [4-(heteroaryl)piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (Glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
09/15/2010CN101125205B Polyethylene decorative nevin fibrinolytic enzyme and its preparation method
09/15/2010CN101069742B Pancreatic kininogenase tablet and preparing method
09/15/2010CN101035792B Novel diazabicyclic aryl derivatives and their medical use
09/15/2010CN101002841B Effective components of rose, its preparing method and use
09/14/2010US7795494 Transgenic animals capable of generating antibodies, e.g., human monoclonal antibodies, specific for the product of a gene of interest
09/14/2010US7795453 6-[(Anilinocarbonyl)amino]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamide hydrochloride; treatment of dementia, attention deficit hyperactivity disorder and impairments of learning and memory
09/14/2010US7795450 aministering N-(2,4-di-n-amylpentanoic acid amide)-tryptophanamide, for the treatment of diseases associated with the decreased binding of magnesium to the plasma membranes of their cells, such as hypertension, diabetes, non-insulin depepndent diabetes, pre-eclampsia and eclampsia
09/14/2010US7795428 Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; preparing, for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile
09/14/2010US7795289 Use of acylaminothiazole derivatives as therapeutic agents
09/14/2010US7795267 G protein-coupled receptor antagonists such as phenyl tetrahydro-3-oxo-1,1-diphenyl-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxylate, used for treating cancer, Alzheimer's disease, dementia, eating disorder, hypertension, glandular disorders, diabetes and hyperlipemia
09/14/2010US7795266 Tetrahydroindolone derivatives for treament of neurological conditions
09/14/2010US7795261 substance P receptor blockers, such as [2R-trans]-{2-benzyl-4-[4-(1-pyrazin-2-yl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone, used for treating schizophrenia, emesis, anxiety and depression, irritable bowel syndrome, sleep disorders, pain and inflammation
09/14/2010US7795214 polypeptide with at least one amino acid replacement at position at 132, 134, 170, or 181; agonist of MET receptor; induce DNA synthesis, protect from liver damage from acetaminophen; gene therapy; promote cell growth angiogenesis, treatment of cardiovascular, hepatic, musculoskeletal, neuronal diseases
09/14/2010US7795031 Neurodegenerative disease; demyelination diseases; brain disorders; screening stem cells in brain; animal models; Alzheimer's, Parkinson's, Huntington's disease
09/14/2010US7795021 CNS glial restricted precursor cells which generate oligodendrocytes and at least two distinct populations of astrocytes, but not neurons; isolated from a mixture of cells by positive immunoselection with an A2B5 antibody
09/14/2010US7795018 expresses CD14, CD34, CD45, type I collagen, and HLA-DR; differentiates into osteoblasts, skeletal myoblasts or chondrocytes; obtained by culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin; noninvasive; will not cause rejection at the time of cell transplantation
09/14/2010US7794995 use of several sequential steps, including subcellular fractionation to isolate a plasma membrane fraction and the use of gel filtration or chromatography that separates molecules according to their size or affinity; drug screening
09/14/2010US7794748 Stable oral solid drug composition
09/14/2010US7794728 Induction immunology response; vaccines
09/14/2010US7794719 variable regions peptides for immunizing against amyloid plaque formation; biodrug for dementia, Alzheimer's disease, neuropathy, Down's syndrome, Creutzfeld Jacob disease, Parkinson's disease, amyotropic lateral sclerosis; neuroprotectants; hemostatic agent
09/14/2010CA2633573C Inhibition of tau-tau-association
09/14/2010CA2601600C Substituted aryl 1,4-pyrazine derivatives
09/14/2010CA2536144C Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
09/14/2010CA2441501C Rho-kinase inhibitors
09/14/2010CA2434834C 6-substituted pyrido-pyrimidines
09/14/2010CA2343569C Mammalian transforming growth factor beta - 9
09/13/2010CA2658076A1 Metallic ion chelating agents, method for producing them and use of same
09/10/2010WO2010102248A2 Molecular tweezers for the treatment of amyloid-related diseases
09/10/2010WO2010102003A2 Alkylsulfonyl-2,3-dihydrospiro[indene-1,4'-piperidine] analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
09/10/2010WO2010101587A1 Use of hypoxanthine for promotion of neuronal outgrowth
09/10/2010WO2010101164A1 Pyridine derivative
09/10/2010WO2010100650A2 Therapeutic uses of mastic gum fractions
09/10/2010WO2010100606A1 Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
09/10/2010WO2010100512A1 Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for them preparation
09/10/2010WO2010100431A1 Pyrrolopyrimidines used as kinase inhibitors
09/10/2010WO2010100428A2 Compositions and methods
09/10/2010WO2010100414A1 Abuse resistant formulation
09/10/2010WO2010100396A1 Modified omci as a complement inhibitor
09/10/2010WO2010100312A1 Neuroprotective compounds
09/10/2010WO2010100257A1 Pharmaceutical compositions active in preventing, stabilizing and treating alzheimer's disease
09/10/2010WO2010100247A1 Novel therapy for anxiety
09/10/2010WO2010100133A2 Indole derivatives for treating neurodegenerative diseases
09/10/2010WO2010100060A2 Method for increasing endogenous plasmalogen levels in mammals
09/10/2010WO2010100050A1 Pyridine-2-yl-carboxylic acid amides
09/10/2010WO2010099938A1 Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
09/10/2010WO2010099703A1 Novel uses of fibrinogen-420 and active domain thereof
09/10/2010WO2010099612A1 Antibodies and epitopes specific to misfolded prion protein
09/10/2010WO2010054336A3 Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
09/10/2010WO2010054324A3 Methods for treating clinical conditions associated with lipoprotein lipase activity
09/10/2010WO2010052448A3 Fused pyrazine derivatives as kinase inhibitors
09/10/2010WO2010048446A3 Modulation of axon degeneration
09/10/2010CA2754565A1 Compositions of polymeric myrcene
09/10/2010CA2754564A1 Therapeutic uses of mastic gum fractions
09/10/2010CA2754446A1 Pyridine derivative
09/10/2010CA2754330A1 Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
09/10/2010CA2754283A1 Indole derivatives for treating neurodegenerative diseases
09/10/2010CA2754089A1 Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
09/10/2010CA2753991A1 Secreted ap2 and methods of inhibiting same
09/10/2010CA2753664A1 Abuse resistant formulation
09/10/2010CA2753621A1 Antibodies and epitopes specific to misfolded prion protein
09/10/2010CA2753236A1 Pyrrolopyrimidines used as kinase inhibitors
09/10/2010CA2751534A1 Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
09/10/2010CA2750911A1 Compositions and methods
09/10/2010CA2750010A1 Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
09/09/2010US20100228018 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/09/2010US20100227934 Therapeutic compounds and methods of use
09/09/2010US20100227933 Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitors
09/09/2010US20100227927 Salts of tramadol and naproxen and their crystal forms in the treatment of pain
09/09/2010US20100227916 N-desmethyl-doxepin and methods of using the same to treat sleep disorders
09/09/2010US20100227907 Method of Treating Pain by Using Opioids and CAMKIV Inhibitors
09/09/2010US20100227888 Modulators of cftr
09/09/2010US20100227887 Pyridine-2-yl carboxylic acid amides
09/09/2010US20100227886 Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
09/09/2010US20100227885 Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
09/09/2010US20100227883 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
09/09/2010US20100227873 Nitrogen-containing heterocyclic compounds and methods of use thereof
09/09/2010US20100227870 Novel Compounds
09/09/2010US20100227869 Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands
09/09/2010US20100227865 Oligomer-Beta Blocker Conjugates
09/09/2010US20100227856 Novel compounds
09/09/2010US20100227852 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
09/09/2010US20100227848 Oxo bridged diazepan orexin receptor antagonists
09/09/2010US20100227847 Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators
09/09/2010US20100227844 Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
09/09/2010US20100227828 New synergistic phytochemical composition for the treatment of obesity
09/09/2010US20100227827 Method of increasing tryptophan and nicotinamide levels in vivo
09/09/2010US20100227822 Targeted delivery of botulinum toxin to the sphenopalatine ganglion
09/09/2010US20100227816 Use of GLP-1 Analogues for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission
09/09/2010US20100227814 Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
09/09/2010US20100227794 Smart contrast agent and method for detecting transition metal ions and treating related disorders
09/09/2010US20100227354 Autoimmune Conditions and NADPH Oxidase Defects
09/09/2010US20100227002 Antioxidant compositions comprising extracts of myrtle and rosemary
09/09/2010US20100226981 Oral dosage forms having a high loading of a gabapentin prodrug
09/09/2010US20100226979 Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
09/09/2010US20100226978 Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
09/09/2010US20100226969 Compounds for inhibiting protein aggregation, and methods for making and using them
09/09/2010US20100226921 Methods for treating obesity using Fibroblast Growth Factor-Like Polypeptides
09/09/2010US20100226920 Medical delivery device for therapeutic proteins based on single domain antibodies
09/09/2010US20100226913 Therapeutic Compositions Comprising Monoterpenes
1 ... 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 ... 1833